Smart Share Global Ltd (EM) Stock News

VanEck's NLR nuclear-focused ETF and First Trust's EMLP energy infrastructure fund offer different approaches to energy sector investing. NLR delivers higher 5-year returns (148% growth on $1,000) with lower fees (0.52%), but experiences greater volatility. EMLP provides more stable returns with half the volatility and MLP tax advantages, though with higher expense ratio (0.95%) and lower growth. The choice depends on investor risk tolerance and whether they prefer nuclear energy exposure or traditional pipeline/utility infrastructure.

Schall, Brown & Schwartz LLP has filed a class action lawsuit against Embecta Corp. (NASDAQ: EMBC) for alleged violations of securities laws. The lawsuit claims the company made false and misleading statements regarding its fiscal guidance for Q2 and full-year 2026, failing to disclose known market headwinds in the pen needle sector. The class period runs from November 25, 2025 to May 4, 2026, with a deadline of August 17, 2026 for investors to participate.

The article compares two international ETFs: NZAC, a climate-focused global fund with over 50% U.S. exposure, and IEMG, an emerging markets fund with true international diversification. IEMG offers lower costs (0.09% vs 0.12%), higher yields (2.3% vs 2.0%), and stronger 1-year returns (33.4% vs 19.8%), making it the better choice for emerging market exposure. NZAC delivered stronger 5-year growth ($1,591 vs $1,444 on $1,000) with lower volatility but behaves more like a climate-filtered U.S. tech portfolio than a true international diversifier.

Valeo SE has announced the exercise of its make-whole redemption option for €750 million of 5.375% Sustainability Linked Bonds due 28 May 2027. The redemption will occur on 24 August 2026, with the make-whole redemption amount to be calculated and published around 18 August 2026. All redeemed notes will be cancelled and delisted from Euronext.

Valeo SE has announced the exercise of its make-whole redemption option for €750 million in 5.375% Sustainability Linked Bonds due May 28, 2027. The early redemption is scheduled for August 24, 2026, with the redemption amount to be calculated and published by August 18, 2026. The bonds will be delisted from Euronext following redemption.

Klépierre, Europe's leading shopping center operator, has published its H1 2026 semi-annual financial report on August 6, 2026. The company's portfolio is valued at €21.8 billion as of June 30, 2026, encompassing major shopping centers across over ten European countries attracting 720+ million visitors annually. The company will report nine-month activity results on October 21, 2026.

Hagens Berman is investigating Embecta Corp. (NASDAQ: EMBC) for allegedly misleading investors about the stability of its insulin pen needle business. The company claimed its pen needle portfolio was 'stable' and 'resilient' while experiencing significant competitive share loss and market volume softness. On May 5, 2026, Embecta revealed massive revenue declines, slashed full-year 2026 adjusted EPS guidance by 43%, and cut its quarterly dividend by 93%, causing the stock to plummet 57.8% in a single trading day. Investors with substantial losses during the class period (Nov. 25, 2025 – May 4, 2026) are encouraged to participate in the lawsuit with a lead plaintiff deadline of August 17, 2026.

Class action lawsuits have been filed against four publicly-traded companies alleging securities fraud. Erasca faces allegations regarding misleading preclinical data comparisons; Via Transportation failed to disclose declining ARR and regulatory issues; Embecta misrepresented guidance and segment weakness; and Zillow mischaracterized its Redfin agreement and downplayed antitrust risks. Investors have until mid-August 2026 to file lead plaintiff motions.

Embecta Corp. (NASDAQ: EMBC) faces a securities class action lawsuit for allegedly misleading investors about fiscal year 2026 performance. The company promised flat-to-down-2% revenue and $2.80-$3.00 EPS but delivered a 17.4% revenue collapse and slashed earnings guidance by nearly half. The stock plummeted 57.8% on May 5, 2026, from $9.25 to $3.90. The lawsuit alleges management knew of U.S. market weakness when reaffirming guidance between November 25, 2025 and February 5, 2026.

Hagens Berman is investigating Embecta Corp. for alleged securities law violations, claiming the company misrepresented the stability of its insulin pen needle business. On May 5, 2026, Embecta revealed significant revenue decline, slashed full-year EPS guidance by 43%, and cut its quarterly dividend by 93%, causing the stock to plummet 57.8% in a single trading day. The class action lawsuit covers the period from November 25, 2025 to May 4, 2026, with a lead plaintiff deadline of August 17, 2026.

Schall, Brown & Schwartz LLP has filed a class action lawsuit against Embecta Corp. (NASDAQ: EMBC) for alleged violations of securities laws. The lawsuit claims the company made false and misleading statements regarding its fiscal guidance for Q2 and full-year 2026, failing to disclose known market headwinds in the pen needle sector. The class period runs from November 25, 2025 to May 4, 2026, with a deadline of August 17, 2026 for shareholders to participate.

Rosen Law Firm is notifying Embecta Corp. investors who purchased stock between November 25, 2025 and May 4, 2026 about a securities class action lawsuit. The lawsuit alleges that Embecta made false and misleading statements regarding its fiscal results and guidance, specifically touting its pen needle business as 'incredibly resolute' before missing expectations and cutting 2026 guidance. Investors with losses exceeding $100,000 are encouraged to join the class action before the August 17, 2026 lead plaintiff deadline.

FORVIA announced its H1 2026 financial results on July 31, 2026, reporting margin expansion and strong net cash flow generation. The company confirmed its full-year guidance, demonstrating progress on its IGNITE strategic roadmap. The financial report has been filed with the French financial authority and is available on the company's investor relations website.

Hagens Berman is investigating Embecta Corp. for alleged securities law violations, claiming the company misrepresented the stability of its insulin pen needle business. Embecta's stock plummeted 57.8% after revealing significant revenue decline, slashing full-year EPS guidance by 43% and cutting its quarterly dividend by 93%. The class action lawsuit covers the period from November 25, 2025 to May 4, 2026, with a lead plaintiff deadline of August 17, 2026.

A class action lawsuit has been filed against Black Rock Coffee Bar, Inc. on behalf of investors who purchased shares during its September 2025 IPO or between September 12, 2025 and May 12, 2026. The lawsuit alleges that the company missed consensus earnings estimates in Q1 2026, reporting GAAP EPS of $0.02 (missing by $0.01) and revenue of $55.5 million (missing by $1.14 million). Investors have until August 17, 2026 to apply to be appointed as lead plaintiff.

iBUYPOWER, a gaming PC system integrator with 25 years of experience, has expanded into the professional workstation market with a new line of prebuilt and custom systems. The company simultaneously enhanced its warranty coverage to three years for both parts and labor, up from two years previously. The workstation lineup ranges from $3,349 to $19,149 and features configurations with Intel Core Ultra, AMD Ryzen, and high-end GPU options including NVIDIA RTX PRO Blackwell.

Rosen Law Firm is reminding Embecta Corp. investors who purchased stock between November 25, 2025 and May 4, 2026 of an August 17, 2026 deadline to join a securities class action lawsuit. The lawsuit alleges that Embecta made false and misleading statements about its fiscal results and guidance, particularly regarding its pen needle business, which it described as 'incredibly resolute' before missing expectations and cutting 2026 guidance.

Digital Currency X Technology Inc. (Nasdaq: DCX) signed a non-binding memorandum of understanding with Whales AI Limited to commercialize an AI-powered STEM education robotics platform across the United States and Canada. DCX intends to invest US$20 million to support platform development and will serve as the exclusive territory agent, with revenue to be shared 60/40 (DCX/Whales AI). The agreement is subject to due diligence, final terms negotiation, and board approval, with no revenue expected in the current financial year.

Shareholder class action lawsuits have been filed against Embecta Corp. and Via Transportation Inc., with allegations of false statements and failure to disclose segment weakness and revenue guidance disruptions. Additionally, Holzer & Holzer, LLC announced an investigation into ADTRAN Holdings Inc. regarding potential federal securities law violations. Investors who suffered losses during the relevant periods are encouraged to contact the law firm.

Following the announcement of its proposed merger with WDP, Standard & Poor's has placed ARGAN's BBB- credit rating on CreditWatch with positive outlook, signaling a potential upgrade of at least one notch. S&P cited the merger's expected benefits including increased size, strengthened rental income profile, expanded geographic diversification, and reduced client concentration risk, positioning the combined entity as a European logistics real estate leader.

Embecta Corp. faces a securities fraud class action lawsuit after its stock plummeted 57.8% on May 5, 2026, when the company revealed disappointing Q2 results and admitted to significant market softness in insulin pens and pen needles. Investors allege the company misrepresented the strength of its insulin pen portfolio prior to the announcement. The lead plaintiff deadline is August 17, 2026.

A class action lawsuit has been filed against ADMA Biologics for allegedly making false statements about its business operations. The lawsuit claims the company engaged in undisclosed related party transactions, used channel stuffing to inflate revenues, and lacked adequate internal controls. Following a short report by Culper Research on March 24, 2026, ADMA's stock fell 16.63%. Investors who purchased shares between August 9, 2024 and March 25, 2026 can join the lawsuit with a deadline of August 10, 2026.

Rosen Law Firm is reminding investors who purchased Embecta Corp. common stock between November 25, 2025 and May 4, 2026 of the August 17, 2026 lead plaintiff deadline in an ongoing securities class action. The lawsuit alleges that Embecta made false and misleading statements about its fiscal results and guidance, particularly regarding its pen needle business, which it described as 'incredibly resolute' before missing expectations and cutting 2026 guidance.

Rosen Law Firm is notifying investors about multiple securities class action lawsuits. The primary focus is on Embecta Corp., where investors who purchased stock between November 25, 2025 and May 4, 2026 may be entitled to compensation. The lawsuit alleges that Embecta made false statements about its fiscal results and guidance, particularly regarding its pen needle business, which it described as 'incredibly resolute' before missing expectations and cutting 2026 guidance. The lead plaintiff deadline is August 17, 2026. Similar class actions are also mentioned for Calix, Inc. and Lucid Group, Inc.

Soitec reports on its liquidity contract managed by BNP Paribas for the first half of 2026. During H1 2026, 227,346 shares were purchased for €17.36 million and 288,875 shares were sold for €23.29 million across 4,546 transactions. The liquidity account held 24,442 shares and €6.36 million as of June 30, 2026.

A class action lawsuit has been filed against Zillow Group, Inc. for allegedly making false and misleading statements regarding its agreement with Redfin Corporation. The lawsuit claims Zillow mischaracterized the Redfin deal as a partnership rather than an acquisition, failed to disclose heightened regulatory and antitrust risks, and downplayed legal exposure. Investors who purchased Zillow stock between February 11, 2025 and May 7, 2026 have until August 10, 2026 to apply as lead plaintiff.

Embecta Corp. (EMBC) faces a securities class action lawsuit for allegedly concealing material risks to its pen needle business. The company provided reassuring guidance in February 2026 but reported a shocking 61% sequential EPS decline in Q2 2026, with pen needle revenues suffering massive declines. Embecta slashed its full-year EPS guidance by 43% and cut its dividend by 93%, triggering significant shareholder losses.

ARCpoint Inc. (TSXV: ARC), a healthcare technology company, announced it will miss its July 29, 2026 filing deadline for annual financial statements due to lack of available funds to pay auditors. The company has applied for a Management Cease Trade Order (MCTO) and expects to file by September 29, 2026. During the MCTO period, insiders will be restricted from trading shares, though public trading will continue.

Brancous LP1, a shareholder of Braemar Hotels & Resorts, criticizes the Board for wasting company resources attacking shareholders instead of negotiating a lower Ashford termination payment. The shareholder claims the Board is pursuing a 'stealth liquidation' through asset sales to trigger a $480 million Change of Control payment to Ashford, which Brancous estimates at $7.00 per share. Brancous demands the Board declare a special dividend of at least $1.00 per share, renegotiate the Ashford payment, and allow shareholders to elect an independent Board.

Rosen Law Firm is soliciting investors who purchased shares of Embecta Corp., Nano-X Imaging Ltd., and Lucid Group, Inc. during specified periods to join securities class action lawsuits. The lawsuits allege that these companies made false or misleading statements regarding financial guidance and business performance. Investors with losses exceeding $100,000 are encouraged to secure counsel before the August 17, 2026 lead plaintiff deadline.